In all treatment conditions, a core set of transcription factors (KLF13, TBX2, TWIST1, and FEV) were maintained as CRC components, with relatively stable super-enhancers and expression levels (Figure 6B). This evidence concerns the gene TWIST1 and colorectal carcinoma.